Perspective Therapeutics Files 8-K
Ticker: CATX · Form: 8-K · Filed: Jun 3, 2025 · CIK: 728387
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Perspective Therapeutics filed an 8-K on 6/3/25. No major news, just standard reporting.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The company, formerly known as Isoray, Inc., is incorporated in Delaware and headquartered in Seattle, Washington.
Why It Matters
This filing indicates routine corporate reporting, providing updates on the company's operational and financial status to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for other events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-33407 — Commission File Number (Identifies the company's SEC filing history)
- 41-1458152 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Isoray, Inc. (company) — Former company name
- June 03, 2025 (date) — Date of report
- Seattle, Washington (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of June 3, 2025.
What was Perspective Therapeutics, Inc. previously known as?
Perspective Therapeutics, Inc. was formerly known as Isoray, Inc.
Where is Perspective Therapeutics, Inc. headquartered?
The company's principal executive offices are located in Seattle, Washington.
What is the company's state of incorporation?
Perspective Therapeutics, Inc. is incorporated in Delaware.
What is the SIC code for Perspective Therapeutics, Inc.?
The Standard Industrial Classification code for Perspective Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Perspective Therapeutics, Inc. (CATX).